{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:05:42Z","timestamp":1792076742368,"version":"4.4.0"},"reference-count":259,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Amphotericin B (AmB), a broad-spectrum polyene antibiotic in the clinic for more than fifty years, remains the gold standard in the treatment of life-threatening invasive fungal infections and visceral leishmaniasis. Due to its poor water solubility and membrane permeability, AmB is conventionally formulated with deoxycholate as a micellar suspension for intravenous administration, but severe infusion-related side effects and nephrotoxicity hamper its therapeutic potential. Lipid-based formulations, such as liposomal AmB, have been developed which significantly reduce the toxic side effects of the drug. However, their high cost and the need for parenteral administration limit their widespread use. Therefore, delivery systems that can retain or even enhance antimicrobial efficacy while simultaneously reducing AmB adverse events are an active area of research. Among those, lipid systems have been extensively investigated due to the high affinity of AmB for binding lipids. The development of a safe and cost-effective oral formulation able to improve drug accessibility would be a major breakthrough, and several lipid systems for the oral delivery of AmB are currently under development. This review summarizes recent advances in lipid-based systems for targeted delivery of AmB focusing on non-parenteral nanoparticulate formulations mainly investigated over the last five years and highlighting those that are currently in clinical trials.<\/jats:p>","DOI":"10.3390\/pharmaceutics12010029","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T11:55:07Z","timestamp":1578052507000},"page":"29","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":193,"title":["Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy"],"prefix":"10.3390","volume":"12","author":[{"given":"C\u00e9lia","family":"Faustino","sequence":"first","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00eddia","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bongomin, F., Gago, S., Oladele, R.O., and Denning, D.W. (2017). Global and multi-national prevalence of fungal diseases\u2013estimate precision. J. Fungi, 3.","DOI":"10.3390\/jof3040057"},{"key":"ref_2","first-page":"1","article-title":"The global burden of fungal diseases","volume":"30","author":"Vallabhaneni","year":"2016","journal-title":"Infect. Dis. Clin."},{"key":"ref_3","unstructured":"LIFE (2019, September 30). Leading International Fungal Education. Fungal Infections. Available online: http:\/\/www.life-worldwide.org\/fungal-diseases."},{"key":"ref_4","unstructured":"GAFFI (2019, September 30). Global Action Fund for Fungal Infections. Fact Sheets. Available online: https:\/\/www.gaffi.org\/media\/fact-sheets\/."},{"key":"ref_5","unstructured":"CDC (2019, September 30). Centers for Disease Control and Prevention. Fungal Diseases, Available online: http:\/\/www.cdc.gov\/fungal\/index.html."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rodrigues, M.L., and Albuquerque, P.C. (2018). Searching for a change: The need for increased support for public health and research on fungal diseases. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006479"},{"key":"ref_7","first-page":"1023","article-title":"Nosocomial fungal infections: Epidemiology, infection control, and prevention","volume":"30","author":"Suleyman","year":"2016","journal-title":"Infect. Dis. Clin."},{"key":"ref_8","unstructured":"(2011, January 18). Fungal Infection Trust. How common are fungal diseases?. Proceedings of the Fungal Research Trust 20th Anniversary Meeting, London, UK. Available online: http:\/\/www.fungalinfectiontrust.org\/wp-content\/uploads\/2019\/08\/How-Common-are-Fungal-Diseases-v12.2.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Chowdhary, A., Sharma, C., and Meis, J.F. (2017). Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006290"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"a019729","DOI":"10.1101\/cshperspect.a019729","article-title":"Fungal biofilms, drug resistance, and recurrent infection","volume":"4","author":"Desai","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wuyts, J., Van Dijck, P., and Holtappels, M. (2018). Fungal persister cells: The basis for recalcitrant infections?. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007301"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.diagmicrobio.2015.06.015","article-title":"Candida tropicalis biofilm\u2019s matrix\u2013involvement on its resistance to amphotericin B","volume":"83","author":"Fernandes","year":"2015","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3201\/eid2302.161320","article-title":"Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris","volume":"23","author":"Sherry","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/AAC.46.6.1773-1780.2002","article-title":"Antifungal susceptibility of Candida biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins","volume":"46","author":"Kuhn","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S1473-3099(17)30306-7","article-title":"Neglected endemic mycoses","volume":"17","author":"Fahal","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","unstructured":"WHO (2019, September 30). World Health Organization: Neglected Tropical Diseases. Available online: https:\/\/www.who.int\/neglected_diseases\/diseases\/en\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-6515-1_2","article-title":"The changing epidemiology of invasive fungal infections","volume":"1508","author":"Enoch","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Friedman, D.Z.P., and Schwartz, I.S. (2019). Emerging fungal infections: New patients, new patterns, and new pathogens. J. Fungi, 5.","DOI":"10.3390\/jof5030067"},{"key":"ref_20","unstructured":"WHO (2019). World Health Organization Model List of Essential Medicines, World Health Organization. Available online: https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Arikan-Akdagli, S., Shannoum, M., and Meis, J.F. (2018). Antifungal resistance: Specific focus on multidrug resistance in Candida auris and secondary azole resistance in Aspergillus fumigatus. J. Fungi, 4.","DOI":"10.3390\/jof4040129"},{"key":"ref_22","first-page":"51","article-title":"Antifungal agents: Spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect. Dis. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/49.suppl_1.7","article-title":"Amphotericin B: Spectrum and resistance","volume":"49","author":"Ellis","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: Side effects and toxicity","volume":"26","year":"2009","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/2211738501999131118125018","article-title":"Amphotericin B formulations\u2013the possibility of generic competition","volume":"1","author":"Serrano","year":"2013","journal-title":"Pharm. Nanotechnol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jac\/44.4.553","article-title":"In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole","volume":"44","author":"Dannaoui","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1099\/jmm.0.075507-0","article-title":"In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates","volume":"63","author":"Montagna","year":"2014","journal-title":"J. Med. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.44.6.1734-1736.2000","article-title":"In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum","volume":"44","author":"Li","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1439-0507.2000.00606.x","article-title":"In vitro susceptibilities of Paracoccidioides brasiliensis yeast form to antifungal drugs","volume":"43","author":"Hahn","year":"2000","journal-title":"Mycosis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1469-0691.2008.02021.x","article-title":"In vitro susceptibility of Cryptococcus gatti clinical isolates","volume":"14","author":"Zaragoza","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1469-0691.2009.02984.x","article-title":"In vitro activity of antifungals against zygomycetes","volume":"15","author":"Castelli","year":"2009","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","first-page":"e01671-16","article-title":"Comparative evaluation of Etest, EUCAST, and CLSI methods for amphotericin B, voriconazole, and posaconazole against clinically relevant Fusarium species","volume":"61","author":"Normand","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1128\/AAC.01218-15","article-title":"In vitro activities of eight antifungal drugs against a global collection of genotyped Exserohilum isolates","volume":"59","author":"Chowdhary","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1128\/AAC.45.9.2524-2528.2001","article-title":"In vitro activities of 10 antifungal drugs against 508 dermatophyte strains","volume":"45","author":"Carrillo","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/mmy\/myu010","article-title":"Antifungal susceptibility of Malassezia furfur, Malassezia sympodialis, and Malassezia globosa to azole drugs and amphotericin B evaluated using a broth microdilution method","volume":"52","author":"Rojas","year":"2014","journal-title":"Med. Mycol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1099\/jmm.0.007609-0","article-title":"MICs and minimum fungicidal concentrations of amphotericin B, itraconazole, posaconazole and terbinafine in Sporothrix schenckii","volume":"58","author":"Silveira","year":"2009","journal-title":"J. Med. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/jms.jms_38_17","article-title":"A comparative study on antifungal susceptibility of Penicillium marneffei (Talaromyces marneffei) and nonmarneffei Penicillium species","volume":"32","author":"Singh","year":"2018","journal-title":"J. Med. Soc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/13693780902977984","article-title":"Molecular identification, genotyping, and drug susceptibility of the basidiomycetous yeast pathogen Trichosporon isolated from Turkish patients","volume":"48","author":"Kalkanci","year":"2010","journal-title":"Med. Mycol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kariyawasam, R., Challa, P., Lau, R., and Boggild, A.K. (2019). Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre\u2122 YeastOne\u2122 YO9 platform. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4237-3"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1128\/AAC.47.2.524-528.2003","article-title":"Activities of azithromycin and amphotericin B against Naegleria fowleri In vitro and in a mouse model of primary amebic meningoencephalitis","volume":"47","author":"Goswick","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cuddihy, G., Wasan, E.K., Di, Y., and Wasan, K.M. (2019). The development of oral amphotericin B to treat systemic fungal and parasitic infections: Has the myth been finally realized?. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11030099"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/jps.21179","article-title":"Amphotericin B formulations and drug targeting","volume":"97","author":"Torrado","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijpharm.2008.05.013","article-title":"Effects of aggregation state on the toxicity of different amphotericin B preparations","volume":"361","author":"Espada","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00249-014-0983-8","article-title":"Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments","volume":"43","author":"Kaminski","year":"2014","journal-title":"Eur. Biophys. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"13821","DOI":"10.1021\/jp510245n","article-title":"Self-association of amphotericin B: Spontaneous formation of molecular structures responsible for the toxic side effects of the antibiotic","volume":"118","author":"Starzyk","year":"2014","journal-title":"J. Phys. Chem. B"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/mp300143n","article-title":"Toward understanding of toxic side effects of a polyene antibiotic amphotericin B: Fluorescence spectroscopy reveals widespread formation of the specific supramolecular structures of the drug","volume":"9","author":"Wasko","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1021\/acs.jctc.7b00337","article-title":"Multi-phase solvation model for biological membranes: Molecular action mechanism of amphotericin B","volume":"13","year":"2017","journal-title":"J. Chem. Theory Comput."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1021\/acs.molpharmaceut.8b00572","article-title":"Mechanism of binding of antifungal antibiotic amphotericin B to lipid membranes: An insight from combined single-membrane imaging, microspectroscopy, and molecular dynamics","volume":"15","author":"Grela","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/2211738504666160301233754","article-title":"Pharmacokinetics and renal toxicity of monomeric amphotericin B in rats after a multiple dose regimen","volume":"4","author":"Kang","year":"2016","journal-title":"Pharm. Nanotechnol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbamem.2003.09.010","article-title":"Memebrane permeabilizing activity of amphotericin B is affected by chain length of phosphatidylcholine added as minor constituent","volume":"1617","author":"Matsuoka","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijpharm.2015.08.003","article-title":"Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections","volume":"494","author":"Molero","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.colsurfb.2018.08.016","article-title":"Comparative studies on amphotericin B nanosuspensions prepared by a high pressure homogenization method and an antisolvent precipitation method","volume":"172","author":"Zhou","year":"2018","journal-title":"Colloids Surf. B"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.1021\/bi800334p","article-title":"Complex formation of amphotericin B in sterol-containing membranes as evidenced by surface plasmon resonance","volume":"47","author":"Mouri","year":"2008","journal-title":"Biochemistry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"15875","DOI":"10.1021\/jp905133f","article-title":"On the possibility of the amphotericin B-sterol complex formation in cholesterol- and ergosterol-containing lipid bilayers: A molecular dynamics study","volume":"113","author":"Neumann","year":"2009","journal-title":"J. Phys. Chem. B"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1021\/acs.langmuir.5b04433","article-title":"Membrane sterols modulate the binding mode of amphotericin B without affecting its affinity for a lipid bilayer","volume":"32","author":"Neumann","year":"2016","journal-title":"Langmuir"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1021\/la7008573","article-title":"Fluorescence of Amphotericin B-deoxycholate (Fungizone) monomers and aggregates and the effect of heat-treatment","volume":"23","author":"Stoodley","year":"2007","journal-title":"Langmuir"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/AAC.41.11.2345","article-title":"Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: A new way to improve its therapeutic index","volume":"41","author":"Gaboriau","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nchembio.1496","article-title":"Amphotericin forms an extramembranous and fungicidal sterol sponge","volume":"10","author":"Anderson","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00249-014-1003-8","article-title":"A new look at the antibiotic amphotericin B effect on Candida albicans plasma membrane permeability and cell viability functions","volume":"44","author":"Chudzik","year":"2015","journal-title":"Eur. Biophys. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1073\/pnas.1117280109","article-title":"Amphotericin primarily kills yeast by simply binding ergosterol","volume":"109","author":"Gray","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"14067","DOI":"10.1038\/s41598-018-32301-9","article-title":"Imaging of human cells exposed to an antifungal antibiotic amphotericin B reveals the mechanisms associated with the drug toxicity and cell defence","volume":"8","author":"Grela","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"32780","DOI":"10.1038\/srep32780","article-title":"Molecular organization, localization and orientation of antifungal antibiotic amphotericin B in a single lipid bilayer","volume":"6","author":"Grudzinski","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijmm.2017.03.005","article-title":"ROS formation is a differential contributory factor to the fungicidal action of amphotericin B and micafungin in Candida albicans","volume":"307","author":"Albuquerque","year":"2017","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1128\/AAC.03570-14","article-title":"The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug","volume":"58","author":"Casas","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.micinf.2011.01.015","article-title":"Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst","volume":"13","author":"Scorzoni","year":"2011","journal-title":"Microbes Infect."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e00978-17","DOI":"10.1128\/AAC.00978-17","article-title":"Induction of mitochondrial reactive oxygen species production by itraconazole, terbinafine, and amphotericin B as a mode of action against Aspergillus fumigatus","volume":"61","author":"Shekhova","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1128\/AAC.47.9.2717-2724.2003","article-title":"Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae","volume":"47","author":"Young","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1128\/AAC.00303-10","article-title":"A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14\u03b1-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B","volume":"54","author":"Martel","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbrc.2011.11.023","article-title":"A novel mechanism for an old drug: Amphotericin B in the treatment of visceral leishmaniasis","volume":"416","author":"Chattopadhyay","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1099\/mic.0.000269","article-title":"The fungicidal activity of amphotericin B requires autophagy-dependent targeting to the vacuole under a nutrient-starved condition in Saccharomyces cerevisiae","volume":"162","author":"Yoshioka","year":"2016","journal-title":"Microbiology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1128\/AAC.01283-12","article-title":"New insight into amphotericin B resistance in Aspergillus terreus","volume":"57","author":"Blum","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/jat.2927","article-title":"Alteration in celular viability, pro-inflammatory cytokines and nitric oxide production in nephrotoxicity generation by amphotericin B: Involvement of PKA pathway signaling","volume":"34","author":"Ferreira","year":"2014","journal-title":"J. Appl. Toxicol."},{"key":"ref_73","first-page":"286","article-title":"It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug","volume":"3","author":"Scorzoni","year":"2012","journal-title":"Front. Microbiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jac\/dkh542","article-title":"Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4","volume":"55","author":"Bellocchio","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"37561","DOI":"10.1074\/jbc.M306137200","article-title":"The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor and CD14-dependent mechanism","volume":"278","author":"Sau","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/jac\/dkt055","article-title":"An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity","volume":"68","author":"Chai","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_77","first-page":"301","article-title":"Optimizing efficacy of amphotericin B through nanomodification","volume":"2","author":"Barrattt","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"ref_78","first-page":"53","article-title":"Studies on a new solubilized preparation of amphotericin B","volume":"5","author":"Bartner","year":"1957","journal-title":"Antibiot. Annu."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: A comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1517\/14740338.2013.827168","article-title":"Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B","volume":"12","author":"Loo","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1128\/AAC.01137-08","article-title":"Amphotericin B-induced renal tubular cell injury is mediated by Na+ influx through ion-permeable pores and subsequent activation of mitogen-activated protein kinases and elevation of intracellular Ca2+ concentration","volume":"53","author":"Yano","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.38.2.223","article-title":"Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B","volume":"38","author":"Wasan","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/jps.2600830716","article-title":"Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: Role of lipid transfer protein","volume":"83","author":"Wasan","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1128\/AAC.48.1.333-336.2004","article-title":"Effect of heat-treated amphotericin B on renal and fungal cytotoxicity","volume":"48","author":"Bartlett","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_85","first-page":"141","article-title":"How can micelle systems be rebuilt by a heating process?","volume":"7","author":"Siqueira","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/1520-6017(200102)90:2<124::AID-JPS3>3.0.CO;2-X","article-title":"Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-\u03b1","volume":"90","author":"Hartsel","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jac\/42.6.779","article-title":"In vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating","volume":"42","author":"Petit","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1007\/s11095-004-7686-2","article-title":"Unidirectional inhibition of lipid transfer protein I-mediated transfer of cholesteryl esters between high-density and low-density lipoproteins by amphotericin B lipid complex","volume":"21","author":"Sivak","year":"2004","journal-title":"Pharm. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1128\/AAC.44.6.1598-1603.2000","article-title":"Mild heating of amphotericin B-desoxycholate: Effects on ultrastructure, In vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice","volume":"44","author":"Roovers","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2174\/1381612822666151209151719","article-title":"Super aggregated form of amphotericin B: A novel way to increase its therapeutic index","volume":"22","author":"Zia","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dkg070","article-title":"Heat-induced superaggregation of amphotericin B attenuates its ability to induce cytokine and chemokine production in the human monocytic cell line THP-1","volume":"51","author":"Rogers","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1023\/B:PHAM.0000041449.46054.b4","article-title":"Heat-treated Fungizone retains amphotericin B antifungal activity without renal toxicity in rats infected with Aspergillus fumigatus","volume":"21","author":"Sivak","year":"2004","journal-title":"Pharm. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.43.2.390","article-title":"Activity of a heat-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani","volume":"43","author":"Petit","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exppara.2018.07.017","article-title":"In vitro and in vivo antileishmanial activity of inexpensive amphotericin B formulations: Heated amphotericin B and amphotericin B-loaded microemulsion","volume":"192","author":"Silva","year":"2018","journal-title":"Exp. Parasitol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/cid\/ciz076","article-title":"Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B","volume":"68","author":"Groll","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1093\/cid\/ciz064","article-title":"Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B","volume":"68","author":"Lewis","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1128\/AAC.41.10.2201","article-title":"Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase I and phase II studies","volume":"41","author":"Adedoyin","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1128\/AAC.40.3.609","article-title":"Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia","volume":"40","author":"Montoro","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/AAC.44.10.2900-2902.2000","article-title":"A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections","volume":"44","author":"Adedoyin","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1128\/AAC.00690-12","article-title":"Pharmacokinetics of amphotericin B colloidal dispersion in critically ill patients with cholestatic liver disease","volume":"56","author":"Weiler","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.39.9.2042","article-title":"Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants","volume":"39","author":"Amantea","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1128\/AAC.41.6.1275","article-title":"Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients","volume":"41","author":"Heinemann","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/AAC.42.9.2391","article-title":"Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients","volume":"42","author":"Walsh","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_105","first-page":"S5","article-title":"Liposomal drug delivery system from laboratory to clinic","volume":"51","author":"Kshirsagar","year":"2005","journal-title":"J. Postgrad. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1023\/A:1011923704731","article-title":"Elucidation of human amphotericin B pharmacokinetics: Identification of a new potential factor affecting interspecies pharmacokinetic scaling","volume":"15","author":"Robbie","year":"1998","journal-title":"Pharm. Res."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Aguirre, J.P.B., and Hamid, A.M.R. (2015). Amphotericin B deoxycholate versus liposomal amphotericin B: Effects on kidney function. Cochrane Database Syst. Rev., 23.","DOI":"10.1002\/14651858.CD010481.pub2"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/myc.12283","article-title":"Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: A real-life study","volume":"58","author":"Falci","year":"2015","journal-title":"Mycoses"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/myc.12585","article-title":"Efficacy and safety of amphotericin B lipid-based formulations\u2013A systematic review and meta-analysis","volume":"60","author":"Steimbach","year":"2017","journal-title":"Mycoses"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bcp.13521","article-title":"Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations","volume":"84","author":"Andrew","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e02383-17","DOI":"10.1128\/mBio.02383-17","article-title":"The viscoelastic properties of the fungal cell wall allow traffic of AmBisome as intact liposome vesicles","volume":"9","author":"Walker","year":"2018","journal-title":"MBio"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.langmuir.5b01365","article-title":"Neutron scattering studies of the effects of formulating amphotericin B with cholesteryl sulfate on the drug\u2019s interactions with phospholipid and phospholipid-sterol membranes","volume":"31","author":"Foglia","year":"2015","journal-title":"Langmuir"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jiac.2018.08.011","article-title":"Efficacy of liposomal amphotericin B against four species of Candida biofilms in an experimental mouse model of intravascular catheter infection","volume":"24","author":"Fujimoto","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jiac.2015.05.007","article-title":"In vitro efficacy of liposomal amphotericin B, micafungin and fluconazole against non-albicans Candida species biofilms","volume":"21","author":"Kawai","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijantimicag.2008.07.030","article-title":"Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms","volume":"33","author":"Mukherjee","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1128\/AAC.48.5.1727-1732.2004","article-title":"Rabbit model of Candida albicans biofilm infection: Liposomal amphotericin B antifungal lock therapy","volume":"48","author":"Schinabeck","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/INF.0b013e318170b68b","article-title":"Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy","volume":"27","author":"Buckler","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jpids\/piu083","article-title":"Antifungal lock therapy with liposomal amphotericin B: A prospective trial","volume":"5","author":"McGhee","year":"2016","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/jac\/dkl141","article-title":"Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion","volume":"57","author":"Vogelsinger","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1128\/AAC.44.2.408-410.2000","article-title":"Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits","volume":"44","author":"Groll","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/03639040902824852","article-title":"Differences in human phospholipid transfer protein activity following incubation of Fungizone compared to lipid-based amphotericin-B formulations in normolipidemic and hyperlipidemic plasma","volume":"35","author":"Henderson","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1208\/s12249-015-0406-x","article-title":"Factors affecting enhanced permeation of amphotericin B across cell membranes and safety of formulation","volume":"17","author":"Adhikari","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.lfs.2015.09.004","article-title":"Antifungal antibiotics modulate the pro-inflammatory cytokine production and phagocytic activity of human monocytes in an in vitro sepsis model","volume":"141","author":"Muenster","year":"2015","journal-title":"Life Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1702243","article-title":"Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: Data of a prematurely stopped clinical trial","volume":"25","author":"Timmers","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1128\/AAC.49.4.1397-1403.2005","article-title":"Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B","volume":"49","author":"Simitsopoulou","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1093\/jac\/dkn394","article-title":"Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: Data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry","volume":"62","author":"Paterson","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e02293-17","DOI":"10.1128\/AAC.02293-17","article-title":"Evaluation of amphotericin B lipid formulations for treatment of severe coccidioidomycosis","volume":"62","author":"Sidhu","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/myc.12801","article-title":"Cost-effectiveness of amphotericin B formulations in the treatment of systemic fungal infections","volume":"61","author":"Borba","year":"2018","journal-title":"Mycoses"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1590\/S1413-86702007000200006","article-title":"Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningites in AIDS patients","volume":"11","author":"Rubio","year":"2007","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1128\/AAC.42.4.762","article-title":"Amphotericin B in lipid emulsion: Stability, compatibility, and in vitro antifungal activity","volume":"42","author":"Walker","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jac\/39.3.427","article-title":"In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits","volume":"39","author":"Chavanet","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/13693780310001624583","article-title":"Cytokines in mice treated with amphotericin B-intralipid","volume":"42","author":"Shadkchan","year":"2004","journal-title":"Med. Mycol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13693780310001598871","article-title":"Treatment of murine systemic aspergillosis with polyene-intralipid admixtures","volume":"42","author":"Sionov","year":"2004","journal-title":"Med. Mycol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1128\/AAC.43.6.1417","article-title":"Amphotericin B in children with malignant disease: A comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion","volume":"43","author":"Nath","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.rvsc.2017.12.005","article-title":"Comparison of conventional and lipid emulsion formulations of amphotericin B: Pharmacokinetics and toxicokinetics in dogs","volume":"117","author":"Nieto","year":"2018","journal-title":"Res. Vet. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/mmy.41.1.15.19","article-title":"Pharmacokinetics of amphotericin B in serum and tissues in mice treated with amphotericin B-Intralipid","volume":"41","author":"Shadkchan","year":"2003","journal-title":"Med. Mycol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jphp.12802","article-title":"Efficacy and safety of amphotericin B formulations: A network meta-analysis and a multicriteria decision analysis","volume":"69","author":"Tonin","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4269\/ajtmh.2009.80.700","article-title":"Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis","volume":"80","author":"Sundar","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Sundar, S., Pandey, K., Thakur, C.P., Jha, T.K., Das, V.N., Verma, N., Lal, C.S., Verma, D., Alam, S., and Das, P. (2014). Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: A randomized, open-label study. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003169"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.healun.2008.11.004","article-title":"Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: Pharmacokinetics and safety","volume":"28","author":"Monforte","year":"2009","journal-title":"J. Heart Lung Transplant."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1211\/jpp.57.10.0007","article-title":"Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: Evidence for long-term biological activity","volume":"57","author":"Ruijgrok","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/TP.0b013e3181f995ea","article-title":"Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients","volume":"90","author":"Husain","year":"2010","journal-title":"Transplantation"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/tri.12679","article-title":"10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation","volume":"29","author":"Peghin","year":"2016","journal-title":"Transpl. Int."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.healun.2012.11.013","article-title":"Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant","volume":"32","author":"Monforte","year":"2013","journal-title":"J. Heart Lung Transplant."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/jac\/dkr567","article-title":"Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis","volume":"67","author":"Kirkpatrick","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/mmy\/myv111","article-title":"Comparison between liposomal formulations of amphotericin B","volume":"54","author":"Gangneux","year":"2016","journal-title":"Med. Mycol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijpharm.2019.04.052","article-title":"Critical process parameters in manufacturing of liposomal formulations of amphotericin B","volume":"565","author":"Rivnay","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1128\/AAC.00870-07","article-title":"Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products","volume":"52","author":"Olson","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/mmy\/myu070","article-title":"Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice","volume":"53","author":"Olson","year":"2015","journal-title":"Med. Mycol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2018.11.010","article-title":"Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome","volume":"134","author":"Tang","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_154","first-page":"S58","article-title":"Post-marketing study to assess the safety, tolerability and effectiveness of Fungisome: An Indian liposomal amphotericin B preparation","volume":"51","author":"Sanath","year":"2005","journal-title":"J. Postgrad. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2010.07.003","article-title":"Nanosomal amphotericin B is an efficacious alternative to Ambisome for fungal therapy","volume":"397","author":"Sheikh","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_156","first-page":"1000248","article-title":"Topical delivery of lipid based amphotericin B gel in the treatment of fungal infection: A clinical efficacy, safety and tolerability study in patients","volume":"5","author":"Sheikh","year":"2014","journal-title":"J. Clin. Exp. Dermatol. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2174\/1381612822666161027103640","article-title":"Exploring the role of nanoparticles in amphotericin B delivery","volume":"23","author":"Zaioncz","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425247.2019.1659243","article-title":"Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases","volume":"16","author":"Lanza","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_159","first-page":"1","article-title":"Design of amphotericin B oral formulation for antifungal therapy","volume":"24","author":"Liu","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.drudis.2019.01.004","article-title":"Solid nanoparticles for oral antimicrobial drug delivery: A review","volume":"24","author":"Raza","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2018.04.009","article-title":"Long chain fatty acid conjugation remarkably decreases the aggregation induced toxicity of amphotericin B","volume":"544","author":"Thanki","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1021\/acs.molpharmaceut.9b00662","article-title":"Improved oral bioavailability and gastrointestinal stability of amphotericin B through fatty acid conjugation approach","volume":"16","author":"Thanki","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1021\/acs.bioconjchem.5b00463","article-title":"Taming amphotericin B","volume":"26","author":"Janout","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijpharm.2014.05.066","article-title":"Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation","volume":"471","author":"Gangadhar","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1208\/s12249-018-1013-4","article-title":"Bioactivity, safety, and efficacy of amphotericin B nanomicellar aerosols using sodium deoxycholate sulfate as the lipid carrier","volume":"19","author":"Usman","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Usman, F., Nopparat, J., Javed, I., and Srichana, T. (2019). Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models. Drug Deliv. Transl. Res.","DOI":"10.1007\/s13346-019-00662-x"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.colsurfa.2014.11.039","article-title":"Solubilization power of an amino acid-based gemini surfactant towards the hydrophobic drug amphotericin B","volume":"480","author":"Faustino","year":"2015","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpharm.2015.11.034","article-title":"Lipoamino acid-based micelles as promising delivery vehicles for monomeric amphotericin B","volume":"497","author":"Serafim","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1208\/s12249-016-0553-8","article-title":"Surface-modified liposomal formulation of amphotericin B: In vitro evaluation of potential against visceral leishmaniasis","volume":"18","author":"Patere","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2014.08.035","article-title":"Study of amphotericin B magnetic liposomes for brain targeting","volume":"475","author":"Zhao","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijpharm.2011.01.044","article-title":"Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B","volume":"408","author":"Iman","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e02525-16","DOI":"10.1128\/AAC.02525-16","article-title":"Biodistribution and in vivo antileishmanial activity of 1,2-distigmasterylhemisuccinoyl-sn-glycero-3-phosphocholine liposome-intercalated amphotericin B","volume":"61","author":"Iman","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.colsurfb.2015.12.003","article-title":"Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro","volume":"139","author":"Perez","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/08982104.2014.995670","article-title":"Nanoethosomal formulation for skin targeting of amphotericin B: An in vitro and in vivo assessment","volume":"25","author":"Kaur","year":"2015","journal-title":"J. Liposome Res."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Asad, M., Bhattacharya, P., Banerjee, A., and Ali, N. (2015). Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME\u212210, a new liposomal amphotericin B. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0928-6"},{"key":"ref_176","first-page":"767","article-title":"Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model","volume":"137","author":"Mishra","year":"2013","journal-title":"Indian J. Med. Res."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Shadab, M., Jha, B., Asad, M., Deepthi, M., Kamran, M., and Ali, N. (2017). Apoptosis-like cell death in Leishmania donovani treated with Kalsome TM10, a new liposomal amphotericin B. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171306"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3109\/10611861003649712","article-title":"A new vaginal delivery system of amphotericin B: A dispersion of cationic liposomes in a thermosensitive gel","volume":"18","author":"Kang","year":"2010","journal-title":"J. Drug Target"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1080\/08927014.2017.1363191","article-title":"Anti-biofilm activity of a sophorolipid-amphotericin B niosomal formulation against Candida albicans","volume":"33","author":"Haque","year":"2017","journal-title":"Biofouling"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejps.2015.01.015","article-title":"Nanoemulsions loaded with amphotericin B: A new approach for the treatment of leishmaniasis","volume":"70","author":"Caldeira","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3109\/03639045.2014.902957","article-title":"Enhanced stability and permeation potential of nanoemulsion containing sefsol-218 oil for topical delivery of amphotericin B","volume":"41","author":"Hussain","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.3109\/10717544.2016.1153747","article-title":"Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of amphotericin B","volume":"23","author":"Hussain","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.nano.2016.12.002","article-title":"New perspectives in the topical delivery of optimized amphotericin B loaded nanoemulsions using excipients with innate anti-fungal activities: A mechanistic and histopathological investigation","volume":"13","author":"Hussain","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.nano.2017.06.021","article-title":"Amphotericin B releasing topical nanoemulsions for the treatment of candidiasis and aspergillosis","volume":"13","author":"Sosa","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijpharm.2009.01.003","article-title":"Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans","volume":"372","author":"Wasan","year":"2009","journal-title":"Int. J. Pharm."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Wasan, E.K., Gershkovich, P., Zhao, J., Zhu, X., Werbovetz, K., Tidwell, R.R., Clements, J.G., Thornton, S.J., and Wasan, K.M. (2010). A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral leishmaniasis in a murine model. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000913"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3109\/03639045.2014.954587","article-title":"Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature","volume":"41","author":"Wasan","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1476-511X-12-158","article-title":"Efficacy of an oral and tropically stable lipid-based formulation of amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis","volume":"12","author":"Ibrahim","year":"2013","journal-title":"Lipids Health Dis."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1049\/iet-nbt.2018.5281","article-title":"Formulations and characterisation of a self-nanoemulsifying drug delivery system of amphotericin B for the treatment of leishmaniasis","volume":"13","author":"Khan","year":"2019","journal-title":"IET Nanobiotechnol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1208\/s12249-018-0986-3","article-title":"Lyotropic liquid crystalline nanoparticles of amphotericin B: Implication of phytantriol and glyceryl monooleate on bioavailability enhancement","volume":"19","author":"Jain","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1208\/s12249-012-9876-2","article-title":"Development of amphotericin B-loaded cubosomes through the SolEmuls technology for enhancing the oral bioavailability","volume":"13","author":"Yang","year":"2012","journal-title":"APPS PharmSciTech"},{"key":"ref_192","first-page":"327","article-title":"Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection","volume":"9","author":"Yang","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/03639045.2014.884129","article-title":"Long-term sustained-released in situ gels of a water-insoluble drug amphotericin B for mycotic arthritis intra-articular administration: Preparation, in vitro and in vivo evaluation","volume":"41","author":"Yue","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.44.9.2356-2360.2000","article-title":"Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis","volume":"44","author":"Santagelo","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e00724-19","DOI":"10.1128\/mBio.00724-19","article-title":"Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis","volume":"10","author":"Lu","year":"2019","journal-title":"MBio"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.intimp.2016.09.008","article-title":"Antifungal and immunomodulatory activity of a novel cochleate for amphotericin B delivery against Sporothrix schenckii","volume":"40","author":"Lastre","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_197","first-page":"4733","article-title":"NanoDisk containing super aggregated amphotericin B: A high therapeutic index antifungal formulation with enhanced potency","volume":"8","author":"Burgess","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.wjorl.2017.01.002","article-title":"Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin, B","volume":"3","author":"Cho","year":"2017","journal-title":"World J. Otorhinolaryngol. Head Neck Surg."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.colsurfb.2015.07.032","article-title":"Topical Amphotericin B solid lipid nanoparticles: Design and development","volume":"139","author":"Butani","year":"2016","journal-title":"Colloids Surf. B"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1166\/jbn.2011.1332","article-title":"AmbiOnp: Solid lipid nanoparticles of amphothericin B for oral administration","volume":"7","author":"Patel","year":"2011","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_201","first-page":"354","article-title":"Solid lipid nanoparticles of amphotericin B (AmbiOnp): In vitro and in vivo assessment towards safe and effective oral treatment module","volume":"6","author":"Chaudhari","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jddst.2018.10.003","article-title":"Nanostructured lipid carriers containing Amphotericin B: Development, in vitro release assay, and storage stability","volume":"48","author":"Santiago","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2174\/1567201812666150326110821","article-title":"Development and characterization of spray dried microparticles for pulmonary delivery of antifungal drug","volume":"12","author":"Mathpal","year":"2015","journal-title":"Curr. Drug Deliv."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s11095-016-1948-7","article-title":"Reformulation of Fungizone by PEG-DSPE micelles: Deaggregation and detoxification of amphotericin B","volume":"33","author":"Alvarez","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_205","first-page":"7265","article-title":"Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles","volume":"10","author":"Chen","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.carbpol.2018.10.086","article-title":"Linolenic acid-modified methoxy poly(ethylene glycol)-oligochitosan conjugate micelles for encapsulation of amphotericin B","volume":"205","author":"Song","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jddst.2018.05.001","article-title":"Development and in vitro evaluation of cost effective amphotericin B polymeric emulsion","volume":"46","author":"Ishaq","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejpb.2014.11.019","article-title":"Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: Biodistribution and toxicity assessment of encapsulated amphotericin B","volume":"89","author":"Asthana","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/mp500527x","article-title":"Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles","volume":"12","author":"Serrano","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/08982104.2016.1224899","article-title":"Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy","volume":"27","author":"Fu","year":"2017","journal-title":"J. Liposome Res."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/10837450.2018.1515225","article-title":"Mucoadhesive chitosan-coated nanostructured lipid carriers for oral delivery of amphotericin B","volume":"24","author":"Roberts","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1208\/s12249-019-1346-7","article-title":"Antifungal and mucoadhesive properties of an orally administered chitosan-loaded amphotericin B nanostructured lipid carrier (NLC)","volume":"20","author":"Ling","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijbiomac.2019.02.076","article-title":"Nanocapsules of Sterculia striata acetylated polysaccharide as a potential monomeric amphotericin B delivery matrix","volume":"130","author":"Sombra","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_214","unstructured":"Najjar, R. (2017). Amino acid-based surfactants for biomedical applications. Application and Characterization of Surfactants, IntechOpen. Available online: https:\/\/www.intechopen.com\/books\/application-and-charcaterization-of-surfactants\/amino-acid-based-surfactants-for-biomedical-applications."},{"key":"ref_215","unstructured":"Hernandez, J. (2015). Phospholipid-based drug delivery systems: Scopes and limitations. Lecithins and Phospholipids: Biochemistry, Properties and Clinical Significance, Nova Science Publishers."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.msec.2014.11.069","article-title":"Development and characterization of oral liposomes of vegetal ceramide based amphotericin B having enhanced dry solubility and solubility","volume":"48","author":"Hallouard","year":"2015","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cis.2013.11.018","article-title":"Niosomes from 80s to present: The state of the art","volume":"205","author":"Marianecci","year":"2014","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Ge, X., Wei, M., He, S., and Yuan, W.-E. (2019). Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11020055"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jconrel.2012.04.004","article-title":"The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection","volume":"160","author":"Alssadi","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"23575","DOI":"10.1038\/srep23575","article-title":"Inhibitory effect of sophorolipid on Candida albicans biofilm formation and hyphal growth","volume":"6","author":"Haque","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1166\/jbn.2012.1385","article-title":"Amphotericin B-loaded nanocarriers for topical treatment of cutaneous leishmaniasis: Development, characterization, and in vitro skin permeation studies","volume":"8","author":"Santos","year":"2012","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.febslet.2006.04.021","article-title":"Binding of antibiotic amphotericin B to lipid membranes: A 1H NMR study","volume":"580","author":"Gabrielska","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/mp700081v","article-title":"Effect of cholesterol on the release of amphotericin B from PEG-phospholipid micelles","volume":"5","author":"Vakil","year":"2008","journal-title":"Mol. Pharm."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Castillo, C., Rodr\u00edguez-Fern\u00e1ndez, C., C\u00f3rdoba, M., and Torrado, J.J. (2018). Permeability characteristics of a new antifungal topical amphotericin B formulation with \u03b3-cyclodextrins. Molecules, 23.","DOI":"10.3390\/molecules23123349"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1476-511X-10-135","article-title":"Tropicall stable novel oral lipid formulation of amphotericin B (iCo-010): Biodistribution and toxicity in a mouse model","volume":"10","author":"Sivak","year":"2011","journal-title":"Lipids Health Dis."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ejps.2012.02.008","article-title":"Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model","volume":"46","author":"Ibrahim","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_227","unstructured":"Rae, A. (2019, November 20). iCo Therapeutics Inc. Provides an Update Regarding Oral Amphotericin Study, Marketing and Partnering Activities. Available online: http:\/\/icotherapeutics.com\/2019\/10\/28\/ico-therapeutics-inc-provides-an-update-regarding-oral-amphotericin-study-marketing-and-partnering-activities\/."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijpharm.2018.01.037","article-title":"Liquid crystalline drug delivery vehicles for oral and IV\/subcutaneous administration of poorly soluble (and soluble) drugs","volume":"539","author":"Otte","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/10837450701555885","article-title":"SolEmuls technology: A way to overcome the drawback of parenteral administration of insoluble drugs","volume":"12","author":"Junghanns","year":"2007","journal-title":"Pharm. Dev. Technol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/08982100009031116","article-title":"Cochleates: New lipid-based drug delivery system","volume":"10","author":"Zarif","year":"2000","journal-title":"J. Liposome Res."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.44.6.1463-1469.2000","article-title":"Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model","volume":"44","author":"Zarif","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.46.8.2704-2707.2002","article-title":"Efficacy of orally delivered cochleated containing amphotericin B in a murine model of aspergillosis","volume":"46","author":"Delmas","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1590\/S0074-02762011000200022","article-title":"In vitro activity of amphotericin B cochleates against Leishmania chagasi","volume":"106","author":"Sesana","year":"2011","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_234","unstructured":"Matinas BioPharma (2019, November 04). Matinas BioPharma Receives Orphan Drug Designation from U.S. FDA for MAT2203 for the Treatment of Cryptococcosis. Matinas BioPharma Press Release. Available online: http:\/\/www.matinasbiopharma.com\/media\/press-releases\/detail\/351\/matinas-biopharma-receives-orphan-drug-designation-from."},{"key":"ref_235","first-page":"1000311","article-title":"Effect of amphotericin B nanodisks on Leishmania major infected mice","volume":"5","author":"Cole","year":"2014","journal-title":"Pharm. Anal. Acta"},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Mishra, V., Bansal, K.K., Verma, A., Yadav, N., Thakur, S., Sudhakar, K., and Rosenholm, J.M. (2018). Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10040191"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2018.10.017","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release","volume":"133","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/2211738511301010054","article-title":"Development and characterization of amphotericin B loaded solid lipid nanoparticles against experimental visceral leishmaniasis","volume":"1","author":"Gupta","year":"2013","journal-title":"Pharm. Nanotechol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/nano4040905","article-title":"Properties of an oral nanoformulation of a molecularly dispersed amphotericin B comprising a composite matrix of theobroma oil and bee\u00b4s wax","volume":"4","author":"Tan","year":"2014","journal-title":"Nanomaterials"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1208\/s12249-015-0438-2","article-title":"Effect of foods status on the gastrointestinal transit of amphotericin B-containing solid lipid nanoparticles in rats","volume":"17","author":"Amekyeh","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijpharm.2016.12.001","article-title":"Correlating gastric emptying of amphothericin B and paracetamol solid lipid nanoparticles with changes in particle surface chemistry","volume":"517","author":"Amekyeh","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1208\/s12249-014-0279-4","article-title":"A gastrointestinal transit study on amphotericin B-loaded solid lipid nanoparticles in rats","volume":"16","author":"Amekyeh","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1208\/s12249-013-0056-9","article-title":"Lipid effects on expulsion rate of amphotericin B from solid lipid nanoparticles","volume":"15","author":"Tan","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.ijbiomac.2014.10.014","article-title":"Amphotericin-B entrapped lecithin\/chitosan nanoparticles for prolonged ocular application","volume":"72","author":"Chhonker","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.colsurfb.2018.03.015","article-title":"Dual alginate-lipid nanocariers as oral delivery systems for amphotericin B","volume":"166","author":"Senna","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijbiomac.2016.03.070","article-title":"Chitosan\/Sterculia striata polysaccharides nanocomplex as a potential chloroquine drug release device","volume":"88","author":"Sombra","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_247","unstructured":"NClinicalTrials.gov Database, U.S. National Institutes of Health, and U.S. National Library of Medicine (2019, November 27). Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000335093","article-title":"Efficacious treatment of non-dermatophyte mould onychomycosis with topical amphotericin B","volume":"223","author":"Lurati","year":"2011","journal-title":"Dermatology"},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"L\u00f3pez, L., V\u00e9lez, I., Asela, C., Cruz, C., Alves, F., Robledo, S., and Arana, B. (2018). A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006653"},{"key":"ref_250","first-page":"77","article-title":"Safety and tolerability of intrathecal liposomal amphotericin B (AmBisome) for cryptococcal meningitis: A retrospective study in HIV-infected patients","volume":"5","author":"Midde","year":"2018","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijantimicag.2011.10.014","article-title":"Efficacy of intrathecal administration of liposomal amphotericin B combined with voriconazole in a murine model of cryptococcal meningitis","volume":"39","author":"Gazzoni","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Diro, E., Blesson, S., Edwards, T., Ritmeijer, K., Fikre, H., Admassu, H., Kibret, A., Ellis, S.J., Bardonneau, C., and Zijlstra, E.E. (2019). A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0006988"},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Rahman, R., Goyal, V., Haque, R., Jamil, K., Faiz, A., Samad, R., Ellis, S., Balasegaram, M., Boer, M.D., and Rijal, S. (2017). Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005635"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: An open-label, non-inferiority, randomized controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciy172","article-title":"Safety and effectiveness of short-course AmBisome in the treatment of post-kala-azar dermal leishmaniasis: A prospective cohort study in Bangladesh","volume":"67","author":"Das","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cmi.2017.11.008","article-title":"Amphotericin B for treatment of visceral leishmaniasis: Systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies","volume":"24","author":"Rodrigo","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1345\/aph.1R703","article-title":"Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B","volume":"47","author":"Ariano","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.322.7286.579","article-title":"Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial","volume":"322","author":"Eriksson","year":"2001","journal-title":"BMJ"},{"key":"ref_259","unstructured":"Matinas BioPharma (2019, November 04). Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis. Matinas BioPharma Press Release. Available online: http:\/\/www.matinasbiopharma.com\/media\/press-releases\/detail\/294\/matinas-biopharma-reports-topline-data-from-phase-2."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/1\/29\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:42:01Z","timestamp":1760362921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/1\/29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":259,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["pharmaceutics12010029"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12010029","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]}}}